PROCEPT BioRobotics Corporation (PRCT) stock analysis

Healthcare · Medical Devices

From the 10-K filed 2026-02-26

Business type: Asset play

How it makes money

It earns revenue by selling surgical robotic systems and accompanying single-use disposable handpieces used primarily for treating prostate enlargement.

Hospitals and surgical centers purchase the company's AquaBeam and HYDROS robotic systems, then provide a recurring stream of purchases via single-use disposable handpieces for each procedure performed. Profit depends heavily on the ongoing utilization of these systems and the expansion of its installed base, as each procedure directly consumes its proprietary disposables.

Demand is driven by the prevalence of benign prostatic hyperplasia in aging male populations and the clinical preference for heat-free waterjet ablation over traditional surgical methods.

What protects it: the moat

It protects its market position through clinical studies, peer-reviewed publications, and proprietary image-guided robotic technology designed for prostate surgery.

Management asserts that its Aquablation therapy represents a paradigm shift by delivering outcomes independent of prostate size, shape, and surgeon experience. It has compiled a clinical evidence body including nine clinical studies and over 150 peer-reviewed publications to support adoption among physicians and professional associations.

However, management notes that physician awareness and experience remain limited, and the novelty of its systems creates commercialization challenges against established surgical alternatives.

What growth costs

It reinvests capital into research and development, sales and marketing efforts, clinical initiatives, and infrastructure improvements to drive adoption.

The company maintains significant operating losses, reporting a net loss of $95.6 million and an accumulated deficit of $641.6 million as of December 31, 2025, driven largely by ongoing investments in commercial expansion and product development.

Manufacturing takes place at its facility in San Jose, California, while components and sub-assemblies are sourced from numerous global suppliers.

About PROCEPT BioRobotics Corporation

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

Other companies in Medical Devices